Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spain launches nationwide narcolepsy count

NCT ID NCT07299097

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. No treatment or intervention is given—this is purely an observational study to gather data on this rare sleep disorder.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

402 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with NT1 and NT2 from Spain.

Ages

0 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

\- Core Group: Inclusion Criteria: 1. Participants with NT1 or NT2 following International Classification of Sleep Disorders, 3rd Edition (ICSD-3) or ICSD-3 text revision (ICSD-3-TR) criteria who are alive at any point during 2023 or 2024. 2. Any age, ethnicity and nationality. 3. Treated / under follow-up in the study site and residing in the hospitals' reference areas. Consideration will be given if participants have changed their address or reached adulthood. Exclusion Criteria 1\. NT1 or NT2 participants who do not reside in the hospitals' reference areas. \- Supplementary Group: Inclusion criteria: 1. Confirmation to have a diagnosis of NT1 or NT2 by a specialist. 2. Participants greater than equal to (≥) 18 years or parents of narcolepsy participants under 18 years of age. 3. Any gender, ethnicity or nationality. 4. Residence in Spain. Exclusion criteria: 1\. Participants without a confirmed NT1 or NT2 diagnosis by a specialist.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Narcolepsy type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

narcolepsy without cataplexy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Narcolepsy type 1 Narcolepsy type 2

Contacts and locations

Locations

  • Hospital Clinic de Barcelona

    Barcelona, 8036, Spain

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital General de Castellón

    Castellon, Castellon, 12004, Spain

  • Hospital La Paz

    Madrid, 28046, Spain

  • Hospital Vall d'Hebrón

    Barcelona, 8035, Spain

  • Hospital Virgen Macarena

    Seville, 41009, Spain

  • Hospital Virgen de las Nieves

    Granada, 18014, Spain

  • Hospital de Araba

    Vitoria-Gasteiz, Álava, 1009, Spain

  • Hospital de Navarra

    Pamplona, Navarre, 31008, Spain

  • Hospital de la Ribera

    Alzira, Valencia, 46600, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.